| Q64082776 | Co-regulatory Network of Oncosuppressor miRNAs and Transcription Factors for Pathology of Human Hepatic Cancer Stem Cells (HCSC) |
| Q55478812 | Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. |
| Q94550269 | Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells |
| Q94593882 | Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer |
| Q97543832 | Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma |
| Q89704722 | Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting |
| Q37718384 | FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells |
| Q90012549 | FGF/FGFR signaling pathway involved resistance in various cancer types |
| Q47777680 | Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. |
| Q38707438 | Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter |
| Q93010007 | Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids |
| Q57756376 | Hepatocellular carcinoma |
| Q103723938 | Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma |
| Q47101174 | IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines |
| Q90466623 | Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma |
| Q90313125 | Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma |
| Q47161820 | Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals |
| Q100533703 | Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib |
| Q90395716 | Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy |
| Q89859447 | Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma |
| Q54976722 | Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. |
| Q91597640 | Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma |
| Q54111915 | Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. |
| Q92306001 | M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma |
| Q90115366 | Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway |
| Q50129419 | MiR-520f promotes cell aggressiveness by regulating fibroblast growth factor 16 in hepatocellular carcinoma |
| Q58020775 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial |
| Q33907588 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. |
| Q92635779 | Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility |
| Q53688760 | Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer. |
| Q92156901 | Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α |
| Q28079205 | Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer |
| Q61808210 | Tobacco smoke induced hepatic cancer stem cell-like properties through IL-33/p38 pathway |
| Q99725659 | Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma |
| Q47832831 | Treatment options after sorafenib failure in patients with hepatocellular carcinoma. |
| Q91386648 | Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma |
| Q91621531 | Tumour evolution in hepatocellular carcinoma |
| Q92500051 | Tumour-specific amplitude-modulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx |
| Q92094478 | miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR |
| Q90278182 | microRNA-454 promotes liver tumor-initiating cell expansion by regulating SOCS6 |